Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387702 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL725690 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL29753859 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9022509 | 0.93 | ADORA2A (0.86) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9022511 | 0.93 | ADORA2A (0.86) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9021653 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL8838160 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9021635 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL8838178 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL11846235 | 0.89 | CYP1A2 (0.80) | CYP1A2ADORA2AADORA2BTHPOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| US-20230273228-A1 | Diagnostic Method and Compounds for the Treatment of Infections Caused by a Pathogen | SOLUTEX GC, S.L. (ES) | 2023-08-31 | — | — | US | claimed |
| EP-4183392-A1 | DIAGNOSTIC METHOD AND COMPOUNDS FOR THE TREATMENT OF INFECTIONS CAUSED BY A PATHOGEN | Solutex GC, S. L. (ES) | 2023-05-24 | — | — | EP | claimed |
| CN-109821019-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2019-05-31 | — | — | CN | claimed |
| WO-2018091689-A1 | SKELETAL MUSCLE HYPERTROPHY INDUCERS | CYTOO (FR) | 2018-05-24 | — | — | WO | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| EP-2204154-A1 | Association of monosaccharides and adenosine and its cosmetic use | L'OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| US-20090137662-A1 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-05-28 | — | — | US | claimed |
| US-6555545-B2 | Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents | NEW YORK UNIVERSITY | 2003-04-29 | — | — | US | claimed |
| EP-1272897-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001058241-A9 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | NEW YORK UNIVERSITY | 2002-01-03 | — | — | US | claimed |
| WO-2001058241-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2001-08-16 | — | — | WO | claimed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | claimed |
| US-6020321-A | Adenosine receptor agonists for the promotion of wound healing | NEW YORK UNIVERSITY (US) | 2000-02-01 | — | — | US | claimed |
| US-5932558-A | PROMOTE MIGRATION OF ENDOTHELIAL CELLS, FIBROBLASTS AND EPITHELIAL CELLS | NEW YORK UNIVERSITY (US) | 1999-08-03 | — | — | US | claimed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | claimed |
| US-5069895-A | ADENOSINE AGONISTS AND ANTAGONISTS | ERNEST GALLO CLINIC & RESEARCH CENTER | 1991-12-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | ADORA2A, ADORA1, ADORA2B | CYP1A2 298/4885ADORA2A 1/4885ADORA2B 3/4885 |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | CYP1A2 1537/4885ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.